This week on Biotech Nation, Dr. Daniel Kraft discusses why mobility is emerging as a key indicator of health, just like heart rate or blood pressure. From wearable tech that tracks your gait to AI-powered exoskeletons and brain-computer interfaces, new innovations are transforming how we measure and maintain movement.
This week on Biotech Nation, Dr. Martin Borch Jensen and Dr. Francisco LePort from Gordian Biotechnology share a bold new approach to fighting diseases of aging before they take hold. Instead of testing one drug at a time, their technology allows scientists to test hundreds of potential treatments at once, making drug discovery faster and more precise. This could change how we treat conditions like arthritis, heart failure, and fatty liver disease.
Not just seeking treatment for every disease, but making sure the treatments we have already developed are being used in every possible way. I speak with Dr. David Fajgenbaum (Fay-gen-baum), a Professor of Translational Medicine and Human Genetics at the University of Pennsylvania School of Medicine, and President of Every Cure.
This week on Biotech Nation, Priovant Therapeutics CEO Ben Zimmer shares how their once-a-day pill could transform the treatment of severe autoimmune diseases like dermatomyositis and non-infectious uveitis. With phase 3 trials in progress, Priovant is offering hope to patients with few modern treatment options.
In this week's episode of BioTech Nation, Dr. David Bearss, President and CEO of Halia Therapeutics, discusses inflammation and its reduction over a lifetime and in response to various incidents. He unveils the inflammasome, a recently discovered protein complex critical in regulating inflammatory responses and its potential in treating chronic diseases like myelodysplastic syndrome and Alzheimer's. Dr. Bearss shares insights into Halia's groundbreaking approach and his relentless pursuit of medical breakthroughs.
Dr. Jim Brown from DURECT talks about their clinical trials for Alcohol-Associated Hepatitis, a condition for which there is no approved treatment.
Sir Rory Collins is a Professor of Medicine and Epidemiology at the University of Oxford and the Principal Investigator of the UK Biobank. With data from half a million people, it has served 30,000 scientists around the world, giving special support to young researchers and scientists in emergent countries.
When is a medical technology company more than a medical technology company? We’ll hear all about it when I speak with Dave Pacitti, the President and Head of the Americas at Siemens Healthineers. They’re out to solve problems bigger than the products they are known for.
Major Depressive Disorder. Serious Depression. PTSD. Alto Neuroscience CEO, Dr. Amit Etkin talks about developing new and innovative drugs tied directly to each patient’s underlying biology. For every drug, there is a test...
Discover how their AI technology is revolutionizing drug discovery with Dr. Vimal Mehta, Co-Founder and CEO BioXcel and how this is leading to the approval of their first drug for agitation in bipolar I and II and schizophrenia, and paving the way for new treatments.
This week on Biotech Nation, Tech Nation Health Chief Correspondent, Dr. Daniel Kraft, talks about “food as medicine" and how eating real, minimally processed food can prevent chronic illnesses like diabetes and heart disease, starting with kids and school lunches. Programs like Eat Real and the federal Food is Medicine initiative are working to improve diets and health nationwide.
This week on BioTech Nation, Dr. Peter Vanderklish, Chief Scientific Officer at Spinogenix discusses their clinical trials focused on regenerating synapses to repair brain connections and offer hope for conditions like Alzheimer's, ALS, schizophrenia and depression. Phase 2 trials are underway. Check their website for patient recruitment information.
This week on BioTech Nation, Dr. Rollie Carlson, CEO of Immunexpress, talks about Sepsis—a deadly condition responsible for 1 in 5 deaths worldwide. Dr. Carlson talks about the FDA-cleared SeptiCyte test, a new tool that can quickly identify Sepsis within an hour, helping doctors treat it faster and avoid unnecessary antibiotics or even death.
This week on BioTech Nation, we talk with Dr. Eben Kirksey about the ethical issues behind CRISPR, the gene-editing tool that made headlines with the birth of the first “CRISPR babies” in China. Dr. Kirksey shares his experiences investigating this controversial experiment and highlights the deeper questions it raises. He stresses the importance of public dialogue, urging us to consider carefully who benefits from such powerful technologies as we shape the future of gene editing.
This week on BioTech Nation, Dr. Daniel Kraft talks about how AI can personalize health advice using data from devices like your smartwatch. He explains how this technology can help people make better choices to stay healthy and avoid major illnesses. Dr. Kraft envisions AI as a personal health coach, offering real-time tips and reminders tailored to each person's needs.
Dr. Avak Kahvejian, Founding CEO of Cellarity, explains their new approach to discovering drugs by using AI to look at how cells behave as a whole, rather than focusing on one part of the problem. This approach could lead to faster development of better treatments, such as a pill for sickle cell disease.
Brian Culley, CEO of Lineage Cell Therapeutics, talks about a new approach to treating diseases called whole cell replacement therapy - which replaces damaged cells with new ones. Lineage is focusing this new therapy on dry age-related macular degeneration (AMD), a leading cause of blindness, through their collaboration with Genentech..
Dr. Daniel Kraft, Tech Nation Health Chief Correspondent introduces "multimodal medicine", combining data like proteomics, wearables, and imaging for early disease detection. He stresses the importance of both advanced diagnostics and listening to patients' stories for effective healthcare.
Dr. Antony Taubman, the former Director of the Intellectual Property Division at the World Trade Organization, discusses the challenges faced during the COVID-19 pandemic, including the rapid development and distribution of 15 billion doses of Covid vaccines, and how international intellectual property rules influenced these efforts.
Part II - We continue our discussion with Dr. Leroy Hood and Dr. Nathan Price about the subject of their book "The Age of Scientific Wellness", delving into the role of artificial intelligence in healthcare and the ability to mine deep data to deliver hyper-personalized recommendations at a scale never before possible.